News

Home/News
News 2017-06-21T13:15:59+00:00
December 6, 2017
Minerva Neurosciences Announces Enrollment of First Patient in Phase 2b Trial of Seltorexant (MIN-202) in Patients With Insomnia Disorder
WALTHAM, Mass., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central ...
December 6, 2017
Two Independent Poster Abstracts Highlighting The Clinical Efficacy of MiMedx Allografts are Recognized at The 2017 Desert Foot Conference
MARIETTA, Ga., Dec. 6, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue ...
December 6, 2017
BioInvent and Transgene collaborate on next generation oncolytic viruses encoding an anti-CTLA-4 antibody to treat solid tumors
STRASBOURG, France & LUND, Sweden--(BUSINESS WIRE)-- Regulatory News: Transgene (TNG.PA) (Euronext Paris: TNG), a company that designs and develops viral-based immunotherapies, and BioInvent International AB (OMXS:BINV), focused on ...
December 6, 2017
STRATA Skin Sciences Announces Departure of Chief Financial Officer
HORSHAM, Pa., Dec. 06, 2017 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (SSKN) (“STRATA”) a medical technology company in Dermatology and Plastic Surgery dedicated to ...
December 5, 2017
CorMedix Inc. Announces Acceptance of Final Post-Marketing Study Data to be Published in the European Journal of Clinical Microbiology and Infectious Diseases
BERKELEY HEIGHTS, NJ / ACCESSWIRE / December 5, 2017 / CorMedix Inc. (NYSE American: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products ...
December 5, 2017
Arena Pharmaceuticals and Everest Medicines Enter into Development and Commercialization Partnership for Ralinepag and Etrasimod in China
SAN DIEGO, Dec. 5, 2017 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (ARNA), a biopharmaceutical company focused on developing novel, small molecule drugs across multiple therapeutic areas, and ...
December 5, 2017
Mateon Announces Preclinical Data Indicating Enhanced Tumor Immune Response of CA4P with Checkpoint Inhibitor
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2017 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (MATN), a biopharmaceutical company developing investigational drugs for the treatment of orphan ...
December 5, 2017
Heron Therapeutics Announces Pricing of Public Offering of Common Stock
SAN DIEGO, Calif.--(BUSINESS WIRE)--Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some ...
December 4, 2017
Heron Therapeutics Announces Public Offering of Common Stock
SAN DIEGO--(BUSINESS WIRE)--Heron Therapeutics, Inc. (HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of ...
December 4, 2017
TRACON Pharmaceuticals Announces Appointment of Brian Daniels, M.D., to Scientific Advisory Board
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted ...
December 4, 2017
Opiant Pharmaceuticals, Inc. Reports Fiscal First Quarter 2018 Financial Results
SANTA MONICA, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals, Inc. (“Opiant”) (OPNT), a specialty pharmaceutical company developing pharmacological treatments for addictions, today reported ...
December 4, 2017
First Patient Enrolled in Phase 3 Trial for ATIR101™ in Adult Patients with Blood Cancer
AMSTERDAM-DUIVENDRECHT, The Netherlands--(BUSINESS WIRE)--Regulatory News: Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developing innovative cell-therapy ...
December 4, 2017
Biophytis has FAMHP Approval to conduct SARA-INT phase 2b Interventional Study of Sarconeos in Sarcopenia in Belgium
PARIS, Dec. 04, 2017 (GLOBE NEWSWIRE) -- BIOPHYTIS (Euronext Growth Paris:ALBPS), a biotechnology company specializing in the development of drug candidates to treat age-related diseases, ...
December 4, 2017
AzurRx BioPharma to Present at the Biotech Showcase 2018 Conference (January 8th)
BROOKLYN, N.Y., Dec. 04, 2017 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (AZRX) (“AzurRx” or the “Company”), a company specializing in the development of non-systemic, recombinant ...
December 4, 2017
Zogenix Announces New Positive Efficacy and Safety Data from Pivotal Phase 3 Clinical Trial of ZX008 in Dravet Syndrome
EMERYVILLE, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) --  Zogenix, Inc. (ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) ...
December 4, 2017
CymaBay Therapeutics Strengthens Management Team with Appointment of Paul Quinlan as General Counsel
NEWARK, Calif., Dec. 04, 2017 (GLOBE NEWSWIRE) -- CymaBay Therapeutics, Inc. (CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic ...
December 4, 2017
La Jolla Pharmaceutical Company Announces Initiation of Pivotal Clinical Study of LJPC‑401 in Patients with Beta Thalassemia
SAN DIEGO, Dec. 04, 2017 (GLOBE NEWSWIRE) -- La Jolla Pharmaceutical Company(LJPC) (the Company or La Jolla) today announced the initiation of a pivotal clinical ...
December 4, 2017
VALNEVA to Conduct Investor and Partnering Meetings during the Annual J.P. Morgan Healthcare Conference
Lyon (France), December 4, 2017 - Valneva SE today announces that its senior management team will hold investor and partnering meetings in San Francisco during ...
November 22, 2017
ABIVAX to Present at German Equity Forum 2017
ABIVAX (ABVX.PA) (Euronext Paris: FR0012333284 – ABVX), an innovative biotechnology company targeting the immune system to eliminate viral and inflammatory diseases, as well as cancer, ...
November 22, 2017
Gemphire to Present at the Piper Jaffray and LD Micro Investor Conferences
LIVONIA, Mich., Nov. 22, 2017 (GLOBE NEWSWIRE) -- Gemphire Therapeutics Inc. (GEMP), a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for cardiometabolic disorders, ...
Page 5 of 48